With its combined dopamine and norepinephrine reuptake inhibition, as well as TAAR1 agonism, solriamfetol provides a novel mechanism of action for the treatment of depression, possibly offering an effective alternative for patients who do not respond well to traditional antidepressants. The gene discussed is TAAR1; the disease is depressive disorder.